Q2 2025 · 13F-HR
Novo Holdings A/Sholdings as filed
Filed 2025-08-14 · accession 0001415889-25-021889
$1.42B
Reported value
29
Positions
2025-06-30
Period end
The Brief · Novo Holdings A/S · Q2 2025
AI · grounded in 13F
Novo Holdings A/S established a new position in VTI valued at $315.6M. The fund also initiated new stakes in BN for $144.2M and ASML for $132.9M. Additional new positions include CRM at $90M, Mirum Pharmaceuticals Inc at $76.3M, and EWTX at $70.1M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 922908769 | VTI | VANGUARD INDEX FDS | $315.6M | 22.3% | 1,038,550 | Common | SOLE |
| 11271J107 | BN | BROOKFIELD CORP | $144.2M | 10.2% | 2,330,830 | Common | SOLE |
| N07059210 | ASML | ASML HOLDING N V | $132.9M | 9.38% | 165,836 | Common | SOLE |
| 79466L302 | CRM | SALESFORCE INC | $90.0M | 6.36% | 330,187 | Common | SOLE |
| 604749101 | MIRM | MIRUM PHARMACEUTICALS INC | $76.3M | 5.39% | 1,500,055 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $70.1M | 4.95% | 5,350,000 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $68.4M | 4.83% | 680,000 | Common | SOLE |
| 75629V104 | RXRX | RECURSION PHARMACEUTICALS IN | $48.9M | 3.45% | 9,665,128 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $44.6M | 3.15% | 1,550,000 | Common | SOLE |
| 01609W102 | BABA | ALIBABA GROUP HLDG LTD | $42.2M | 2.98% | 372,327 | Common | SOLE |
| 04272N102 | AVBP | ARRIVENT BIOPHARMA INC | $40.8M | 2.88% | 1,872,142 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $39.5M | 2.78% | 750,000 | Common | SOLE |
| 09061G101 | BMRN | BIOMARIN PHARMACEUTICAL INC | $36.3M | 2.56% | 660,000 | Common | SOLE |
| 09627Y109 | 2655787D | BLUEPRINT MEDICINES CORP | $34.0M | 2.40% | 264,956 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $33.3M | 2.35% | 2,380,000 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $30.4M | 2.14% | 1,725,000 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $29.8M | 2.10% | 916,160 | Common | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC NEW | $24.4M | 1.72% | 1,200,000 | Common | SOLE |
| 98937L105 | ZBIO | ZENAS BIOPHARMA INC | $21.8M | 1.54% | 2,250,000 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $21.8M | 1.54% | 1,084,432 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $19.5M | 1.38% | 449,392 | Common | SOLE |
| 15678C102 | CBLL | CERIBELL INC | $16.9M | 1.19% | 900,000 | Common | SOLE |
| 92025Y103 | VALN | VALNEVA SE | $13.5M | 0.95% | 2,375,000 | Common | SOLE |
| 35104E100 | FDMT | 4D MOLECULAR THERAPEUTICS IN | $7.4M | 0.52% | 2,000,000 | Common | SOLE |
| 449778109 | IOBTQ | IO BIOTECH INC | $4.7M | 0.33% | 3,354,449 | Common | SOLE |
| 51655R101 | — | LANZATECH GLOBAL INC | $4.3M | 0.30% | 15,814,845 | Common | SOLE |
| 57142B104 | MQ | MARQETA INC | $2.6M | 0.18% | 441,558 | Common | SOLE |
| 00288U106 | ABCL | ABCELLERA BIOLOGICS INC | $2.2M | 0.16% | 652,529 | Common | SOLE |
| 36322Q206 | DMRA | GALECTO INC | $340,703 | 0.02% | 99,913 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.